Mizuho lowered the firm’s price target on Envista (NVST) to $15 from $18 and keeps an Underperform rating on the shares. The firm believes many companies in the dental sector “may post less-than-stellar growth” in Q1. The recent American Dental Association Q1 survey results further reinforce a cautious view, so Mizuho trimmed Q1 estimates for broad dental manufacturers, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVST:
- Envista price target lowered to $16 from $19 at Morgan Stanley
- Envista price target lowered to $21 from $23 at UBS
- Envista price target lowered to $19 from $21 at Wells Fargo
- Positive Outlook for Envista Holdings: Strategic Growth and Strong Brand Drive Buy Rating
- Envista Holdings: Balancing Growth Potential and Management Challenges Amidst Market Recovery